LeMaitre Vascular (NASDAQ:LMAT) Hits New 1-Year High – Should You Buy?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) hit a new 52-week high on Wednesday . The stock traded as high as $93.32 and last traded at $92.85, with a volume of 77802 shares changing hands. The stock had previously closed at $90.39.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Barrington Research reissued an “outperform” rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research note on Friday, September 20th. Lake Street Capital initiated coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 target price on the stock. Finally, JMP Securities upped their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.40.

LeMaitre Vascular Stock Up 2.8 %

The firm’s 50-day moving average is $87.70 and its 200-day moving average is $80.17. The company has a market cap of $2.09 billion, a PE ratio of 59.86, a PEG ratio of 2.41 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same period in the prior year, the firm posted $0.37 EPS. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Activity

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 12,976 shares of the business’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the sale, the chief executive officer now directly owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,251 shares of company stock worth $3,714,994 over the last 90 days. Corporate insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several large investors have recently bought and sold shares of the business. USA Financial Formulas purchased a new position in LeMaitre Vascular in the 3rd quarter valued at approximately $60,000. GAMMA Investing LLC lifted its position in LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares during the period. Truist Financial Corp boosted its holdings in shares of LeMaitre Vascular by 92.1% in the second quarter. Truist Financial Corp now owns 7,054 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 3,381 shares in the last quarter. Driehaus Capital Management LLC raised its position in LeMaitre Vascular by 52.2% in the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of LeMaitre Vascular by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,469 shares of the medical instruments supplier’s stock valued at $861,000 after acquiring an additional 583 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.